vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and TAYLOR DEVICES, INC. (TAYD). Click either name above to swap in a different company.
TAYLOR DEVICES, INC. is the larger business by last-quarter revenue ($11.6M vs $9.1M, roughly 1.3× Protalix BioTherapeutics, Inc.). TAYLOR DEVICES, INC. runs the higher net margin — 17.3% vs -60.3%, a 77.6% gap on every dollar of revenue. On growth, TAYLOR DEVICES, INC. posted the faster year-over-year revenue change (35.7% vs -49.9%). TAYLOR DEVICES, INC. produced more free cash flow last quarter ($4.4M vs $1.6M). Over the past eight quarters, TAYLOR DEVICES, INC.'s revenue compounded faster (-2.7% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Taylor Corporation is a privately owned print and communications company headquartered in North Mankato, Minnesota, and was founded in 1975 by businessman Glen Taylor. The company comprises more than 90 locations and employs nearly 10,000 employees. Taylor has print operations in dozens of U.S. states and multiple countries around the world.
PLX vs TAYD — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $11.6M |
| Net Profit | $-5.5M | $2.0M |
| Gross Margin | 49.4% | 47.0% |
| Operating Margin | -51.1% | 19.2% |
| Net Margin | -60.3% | 17.3% |
| Revenue YoY | -49.9% | 35.7% |
| Net Profit YoY | -184.8% | 90.2% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $11.6M | ||
| Q3 25 | $17.9M | $9.9M | ||
| Q2 25 | $15.7M | $15.6M | ||
| Q1 25 | $10.1M | $10.6M | ||
| Q4 24 | $18.2M | $8.5M | ||
| Q3 24 | $18.0M | $11.6M | ||
| Q2 24 | $13.5M | $12.1M | ||
| Q1 24 | — | $12.3M |
| Q4 25 | $-5.5M | $2.0M | ||
| Q3 25 | $2.4M | $2.2M | ||
| Q2 25 | $164.0K | $3.7M | ||
| Q1 25 | $-3.6M | $2.0M | ||
| Q4 24 | $6.5M | $1.1M | ||
| Q3 24 | $3.2M | $2.7M | ||
| Q2 24 | $-2.2M | $2.5M | ||
| Q1 24 | — | $2.7M |
| Q4 25 | 49.4% | 47.0% | ||
| Q3 25 | 53.4% | 44.8% | ||
| Q2 25 | 62.5% | 48.6% | ||
| Q1 25 | 19.1% | 42.9% | ||
| Q4 24 | 78.7% | 45.5% | ||
| Q3 24 | 53.4% | 47.4% | ||
| Q2 24 | 29.8% | 48.8% | ||
| Q1 24 | — | 46.9% |
| Q4 25 | -51.1% | 19.2% | ||
| Q3 25 | 11.9% | 22.6% | ||
| Q2 25 | 7.5% | 24.2% | ||
| Q1 25 | -41.0% | 19.1% | ||
| Q4 24 | 39.6% | 11.0% | ||
| Q3 24 | 22.2% | 25.0% | ||
| Q2 24 | -18.0% | 20.8% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | -60.3% | 17.3% | ||
| Q3 25 | 13.2% | 22.1% | ||
| Q2 25 | 1.0% | 23.7% | ||
| Q1 25 | -35.8% | 19.0% | ||
| Q4 24 | 35.6% | 12.4% | ||
| Q3 24 | 18.0% | 23.0% | ||
| Q2 24 | -16.4% | 20.5% | ||
| Q1 24 | — | 22.0% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $40.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $67.1M |
| Total Assets | $82.3M | $72.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $40.7M | ||
| Q3 25 | $13.6M | $36.3M | ||
| Q2 25 | $17.9M | $36.0M | ||
| Q1 25 | $19.5M | $35.4M | ||
| Q4 24 | $19.8M | $26.6M | ||
| Q3 24 | $27.4M | $27.1M | ||
| Q2 24 | $23.4M | $31.0M | ||
| Q1 24 | — | $24.6M |
| Q4 25 | $48.2M | $67.1M | ||
| Q3 25 | $52.9M | $64.3M | ||
| Q2 25 | $49.9M | $62.0M | ||
| Q1 25 | $45.2M | $57.8M | ||
| Q4 24 | $43.2M | $55.8M | ||
| Q3 24 | $32.4M | $53.9M | ||
| Q2 24 | $28.6M | $51.2M | ||
| Q1 24 | — | $47.8M |
| Q4 25 | $82.3M | $72.8M | ||
| Q3 25 | $82.3M | $70.3M | ||
| Q2 25 | $78.5M | $71.6M | ||
| Q1 25 | $73.9M | $70.1M | ||
| Q4 24 | $73.4M | $62.9M | ||
| Q3 24 | $61.6M | $61.9M | ||
| Q2 24 | $91.5M | $63.1M | ||
| Q1 24 | — | $54.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $5.7M |
| Free Cash FlowOCF − Capex | $1.6M | $4.4M |
| FCF MarginFCF / Revenue | 17.8% | 38.3% |
| Capex IntensityCapex / Revenue | 4.4% | 11.3% |
| Cash ConversionOCF / Net Profit | — | 2.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $14.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $5.7M | ||
| Q3 25 | $-3.7M | $483.6K | ||
| Q2 25 | $-5.2M | $1.9M | ||
| Q1 25 | $-5.1M | $9.0M | ||
| Q4 24 | $4.0M | $103.1K | ||
| Q3 24 | $4.1M | $-3.6M | ||
| Q2 24 | $-3.6M | $6.5M | ||
| Q1 24 | — | $-685.0K |
| Q4 25 | $1.6M | $4.4M | ||
| Q3 25 | $-4.2M | $298.6K | ||
| Q2 25 | $-5.7M | $491.3K | ||
| Q1 25 | $-5.4M | $8.8M | ||
| Q4 24 | $3.6M | $-620.5K | ||
| Q3 24 | $4.0M | $-3.8M | ||
| Q2 24 | $-3.8M | $6.1M | ||
| Q1 24 | — | $-895.5K |
| Q4 25 | 17.8% | 38.3% | ||
| Q3 25 | -23.7% | 3.0% | ||
| Q2 25 | -36.2% | 3.2% | ||
| Q1 25 | -53.0% | 83.6% | ||
| Q4 24 | 19.6% | -7.3% | ||
| Q3 24 | 22.4% | -33.0% | ||
| Q2 24 | -28.1% | 51.0% | ||
| Q1 24 | — | -7.3% |
| Q4 25 | 4.4% | 11.3% | ||
| Q3 25 | 2.8% | 1.9% | ||
| Q2 25 | 2.8% | 9.3% | ||
| Q1 25 | 3.0% | 1.8% | ||
| Q4 24 | 2.3% | 8.5% | ||
| Q3 24 | 0.5% | 2.1% | ||
| Q2 24 | 1.3% | 3.3% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | 2.86× | ||
| Q3 25 | -1.58× | 0.22× | ||
| Q2 25 | -31.91× | 0.52× | ||
| Q1 25 | — | 4.51× | ||
| Q4 24 | 0.61× | 0.10× | ||
| Q3 24 | 1.27× | -1.35× | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | — | -0.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TAYD
Segment breakdown not available.
